Bank Of New York Mellon Corp X4 Pharmaceuticals, Inc Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.69 - $2.21 $118,123 - $378,336	171,193 New	171,193 $169,000
Q2 2022 Aug 15, 2022	SELL	$0.88 - $1.91 $806 - $1,749	-916 Reduced 0.65%	139,696 $135,000
Q1 2022 May 11, 2022	BUY	$1.48 - $2.58 $127,645 - $222,517	86,247 Added 158.64%	140,612 $246,000
Q1 2021 May 13, 2021	BUY	$6.63 - $10.28 $13,690 - $21,228	2,065 Added 3.95%	54,365 $468,000
Q4 2020 Feb 09, 2021	BUY	$5.41 - $7.4 $17,025 - $23,287	3,147 Added 6.4%	52,300 $336,000
Q3 2020 Nov 12, 2020	BUY	$6.09 - $9.15 $7,624 - $11,455	1,252 Added 2.61%	49,153 $332,000
Q2 2020 Aug 12, 2020	BUY	$7.98 - $10.44 $71,572 - $93,636	8,969 Added 23.04%	47,901 $446,000
Q1 2020 May 06, 2020	BUY	$6.03 - $11.01 $37,500 - $68,471	6,219 Added 19.01%	38,932 $389,000
Q4 2019 Feb 14, 2020	BUY	$9.93 - $14.33 $56,084 - $80,935	5,648 Added 20.87%	32,713 $350,000
Q3 2019 Nov 07, 2019	BUY	$11.06 - $15.75 $144,609 - $205,931	13,075 Added 93.46%	27,065 $343,000
Q2 2019 Aug 12, 2019	BUY	$12.57 - $21.67 $175,854 - $303,163	13,990 New	13,990 $210,000

105

100M

213K

50.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.